Molecular therapy for safeguarding your heart against cardiac dysfunction: Bergenin-based therapy for cardiomyocyte proliferation and heart regeneration: Bergenin decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.01 pm

Little RNA can save you from cardiac hypertrophy and fibrosis: Intracardiac injection of LncRNA NEAT1 protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of LncRNA NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 31/March/2021, 12.11 am
March 30, 2021
Molecular therapy for safeguarding your heart against cardiac dysfunction: Enoxacin-based therapy for cardiomyocyte proliferation and heart regeneration: Enoxacin, commonly used in the treatment of UTI and gonorrhea, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.17 pm
June 26, 2021
Show all

Introduction: What they say:

A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; and Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA shows that “Loss of microRNA-128 promotes cardiomyocyte proliferation and heart regeneration.” This study was published, in the 16 Feb 2018 issue of Nature communications (one of the best journals in science with an impact factor of 12+), by Prof Wang Y, Huang W, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for safeguarding your heart against cardiac dysfunction: Bergenin-based therapy for cardiomyocyte proliferation and heart regeneration: Bergenin decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.01 pm


From significance of the study to public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

Prof Wang’s research team has shown recently that: (1) miRNA-128 is upregulated in terminally differentiated cardiomyocytes (CMs); (2) Overexpression of MiR-128 in cardiomyocytes inhibits cardiomyocyte proliferation and function; (3) Deletion of miR-128 in postnatal cardiomyocytes increase proliferation by increasing the expression of DNA modifying protein SUZ12; (4) Increased expression of Suz12 inhibits the expression of cyclin-dependent kinase inhibitor p27; (5) Down-regulation of p27 results in increased expression of the positive regulators of cell cycle, such as Cyclin E and CDK2; and (6) Deletion of Mir-128: (a) drives adult cardiomyocytes to re-enter into cell cycle; (b) attenuates fibrosis; and (c) suppresses cardiac dysfunction in response to myocardial infarction, suggesting that inhibition of miR-128 expression may promote cardiomyocyte proliferation and heart regeneration.


From research findings to therapeutic opportunity:

This study suggests, for the first time, Bergenin, by decreasing the expression of its target genes, it could decrease the expression of miRNA-128 (fig.1). Thereby, it may: (1) increase the expression of Suz12;(2) decrease the expression of CDK inhibitor p27; (3) increase the expression of gene products that promote cardiac proliferation, including Cyclin E and CDK2;(4) increase the expression of miRNAs that promote cardiac regeneration;(5) increase cardiomyocyte proliferation; (6) suppress fibrosis; (7) promote cardiomyocyte survival/regeneration; (8) promote recovery after myocardial infarction; and (9) extend lifespan (fig 1). Thus, by taking Bergenin, one may preserve myocardial function after myocardial infarction and prevent aging-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that Bergenin, either alone or in combination with any of the known compounds that improve myocardial function,” may heal damaged cardiac tissue; and regenerate new cardiomyocytes after myocardial infarction (fig.2).

Figure 1. Bergenin functions as a Cardioprotective agent. Mechanistic insights into how Bergenin decreases the expression of MiR-128, and CDKI p27, increases the expression of Cyclin E and CDK2, and regulates the expression of other genes that promote cardiac repair and regeneration.

Figure 2. Bergenin functions as a cardioprotective agent through down regulation of MiR-128, CDKI and p27 and up-regulation of Cyclin E and CDK2

Figure 3. While it has been shown earlier that genetic ablation of miR-128 promotes cardiac regeneration, enhances cardiac contractility, and functional recovery after myocardial infarction, the study presented here suggests that Bergenin functions as a cardioprotective agent through down regulation of MiR-128, CDKI p27; and up-regulation of Cyclin E and CDK2.

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Bergenin decrease the expression of MiR-128 and p27 and promote cardiac proliferation, regeneration, and repair?

Amount: $ 1, 500 #

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Molecular therapy for safeguarding your heart against cardiac dysfunction: Bergenin-based therapy for cardiomyocyte proliferation and heart regeneration: Bergenin decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.01 pm, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Introduction: What they say:

A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; and Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA shows that “Loss of microRNA-128 promotes cardiomyocyte proliferation and heart regeneration.” This study was published, in the 16 Feb 2018 issue of Nature communications (one of the best journals in science with an impact factor of 12+), by Prof Wang Y, Huang W, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Little RNA-based therapy may safeguard your heart against cardiac dysfunction: MiRNA-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA LUADT1 (Long non-coding RNA LUAD transcript 1) decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 31/March/2021, 12.30 am


From significance of the study to public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

Prof Wang’s research team has shown recently that: (1) miRNA-128 is upregulated in terminally differentiated cardiomyocytes (CMs); (2) Overexpression of MiR-128 in cardiomyocytes inhibits cardiomyocyte proliferation and function; (3) Deletion of miR-128 in postnatal cardiomyocytes increase proliferation by increasing the expression of DNA modifying protein SUZ12; (4) Increased expression of Suz12 inhibits the expression of cyclin-dependent kinase inhibitor p27; (5) Down-regulation of p27 results in increased expression of the positive regulators of cell cycle, such as Cyclin E and CDK2; and (6) Deletion of Mir-128: (a) drives adult cardiomyocytes to re-enter into cell cycle; (b) attenuates fibrosis; and (c) suppresses cardiac dysfunction in response to myocardial infarction, suggesting that inhibition of miR-128 expression may promote cardiomyocyte proliferation and heart regeneration.


From research findings to therapeutic opportunity:

This study suggests, for the first time, LncRNA LUADT1 (Long non-coding RNA LUAD transcript 1), by decreasing the expression of its target genes, it could decrease the expression of miRNA-128 (fig.1). Thereby, it may: (1) increase the expression of Suz12;(2) decrease the expression of CDK inhibitor p27; (3) increase the expression of gene products that promote cardiac proliferation, including Cyclin E and CDK2;(4) increase the expression of miRNAs that promote cardiac regeneration;(5) increase cardiomyocyte proliferation; (6) suppress fibrosis; (7) promote cardiomyocyte survival/regeneration; (8) promote recovery after myocardial infarction; and (9) extend lifespan (fig 1). Thus, by adopting LncRNA LUADT1-based therapy, one may preserve myocardial function after myocardial infarction and prevent aging-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that LncRNA LUADT1-based therapy, either alone or in combination with any of the known compounds that improve myocardial function,” may heal damaged cardiac tissue; and regenerate new cardiomyocytes after myocardial infarction (fig.2).

This image has an empty alt attribute; its file name is LncRNA-LAUDT1-Promotes-cardiac-proliferation.regeneration-enhances-cardiac-contractility-functional-recovery-after-myocardial-infarction1-770x578.jpg

Figure 1. LncRNA LAUDT1 function as a Cardioprotective agent. Mechanistic insights into how LncRNA LAUDT1 decreases the expression of MiR-128, and CDKI p27, increases the expression of Cyclin E and CDK2, and regulates the expression of other genes that promote cardiac repair and regeneration.

This image has an empty alt attribute; its file name is LncRNA-LAUDT1-Promotes-cardiac-proliferation.regeneration-enhances-cardiac-contractility-functional-recovery-after-myocardial-infarction2-770x578.jpg

Figure 2. LncRNA LUADT1 (Long non-coding RNA LUAD transcript 1) therapy may function as a cardioprotective agent through down regulation of MiR-128, CDKI p27 and up-regulation of Cyclin E and CDK2

This image has an empty alt attribute; its file name is LncRNA-LAUDT1-Promotes-cardiac-proliferation.regeneration-enhances-cardiac-contractility-functional-recovery-after-myocardial-infarction3-770x578.jpg

Figure 3. While it has been shown earlier that genetic ablation of miR-128 promotes cardiac regeneration, enhances cardiac contractility, and functional recovery after myocardial infarction, the study presented here suggests that LncRNA-LAUDT1-based therapy functions as a cardioprotective agent through down regulation of MiR-128, CDKI p27; and up-regulation of Cyclin E and CDK2. And, thereby, it makes those who undergo Sauna (heat/thermal) therapy at regular intervals less susceptible to cardiac dysfunction.

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does LncRNA LUADT1 decrease the expression of MiR-128 and p27 and promote cardiac proliferation, regeneration, and repair?

Amount: $ 1, 500 #

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Little RNA-based therapy may safeguard your heart against cardiac dysfunction: MiRNA-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA LUADT1 (Long non-coding RNA LUAD transcript 1) decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 31/March/2021, 12.30 am, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.